Rational use of tocilizumab in COVID-19.

Jain, Siddharth; Sharma, Shefali Khanna

Jain, Siddharth; Sharma, Shefali Khanna.

Jain S; Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
Sharma SK; Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India sharmashefali@hotmail.com.

Ann Rheum Dis ; 81(11): e213, 2022 11.

Article in English | MEDLINE | ID: covidwho-2152920

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized/therapeutic use; Humans; SARS-CoV-2; Treatment Outcome

Keywords

antirheumatic agents; biological therapy; communicable diseases, imported; cytokines; inflammation

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2020-218519

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google